| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
Blood
|
2009
|
5.87
|
|
2
|
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
|
Blood
|
2013
|
4.17
|
|
3
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
|
J Clin Invest
|
2007
|
2.91
|
|
4
|
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
|
Blood
|
2009
|
2.39
|
|
5
|
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
|
Blood
|
2008
|
2.24
|
|
6
|
Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.
|
Blood
|
2009
|
2.17
|
|
7
|
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.
|
Blood
|
2006
|
1.92
|
|
8
|
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.
|
Blood
|
2008
|
1.86
|
|
9
|
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
|
Blood
|
2007
|
1.69
|
|
10
|
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
|
Blood
|
2012
|
1.63
|
|
11
|
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
|
Blood
|
2014
|
1.58
|
|
12
|
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.
|
Blood
|
2010
|
1.53
|
|
13
|
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.
|
Cancer Cell
|
2012
|
1.52
|
|
14
|
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
|
Blood
|
2007
|
1.51
|
|
15
|
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.
|
Blood
|
2013
|
1.50
|
|
16
|
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
|
Blood
|
2011
|
1.45
|
|
17
|
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
|
J Clin Invest
|
2014
|
1.38
|
|
18
|
Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.
|
Mol Pharm
|
2009
|
1.37
|
|
19
|
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.
|
Blood
|
2010
|
1.34
|
|
20
|
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling.
|
Cancer Res
|
2008
|
1.31
|
|
21
|
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
|
Clin Cancer Res
|
2013
|
1.30
|
|
22
|
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.
|
Blood
|
2009
|
1.25
|
|
23
|
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
|
Clin Cancer Res
|
2010
|
1.21
|
|
24
|
Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T cells.
|
J Virol
|
2002
|
1.21
|
|
25
|
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.
|
Proc Natl Acad Sci U S A
|
2007
|
1.19
|
|
26
|
Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
|
J Immunol
|
2013
|
1.18
|
|
27
|
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
|
Clin Cancer Res
|
2008
|
1.17
|
|
28
|
Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes.
|
J Pharm Sci
|
2007
|
1.11
|
|
29
|
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
|
Blood
|
2011
|
1.10
|
|
30
|
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
|
Hepatology
|
2011
|
1.07
|
|
31
|
Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing.
|
J Control Release
|
2009
|
1.02
|
|
32
|
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
|
Ther Drug Monit
|
2008
|
0.98
|
|
33
|
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
|
Clin Cancer Res
|
2010
|
0.96
|
|
34
|
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
|
Blood
|
2011
|
0.95
|
|
35
|
The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2009
|
0.95
|
|
36
|
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.
|
Blood
|
2010
|
0.92
|
|
37
|
Activation induced differential regulation of stem cell antigen-1 (Ly-6A/E) expression in murine B cells.
|
Cell Immunol
|
2003
|
0.91
|
|
38
|
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
|
Blood
|
2012
|
0.90
|
|
39
|
IP3 receptor-mediated Ca2+ release in naive CD4 T cells dictates their cytokine program.
|
J Immunol
|
2008
|
0.89
|
|
40
|
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders.
|
Clin Cancer Res
|
2012
|
0.89
|
|
41
|
Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
|
Mol Pharm
|
2010
|
0.87
|
|
42
|
Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity.
|
Mol Pharm
|
2012
|
0.87
|
|
43
|
Developmental anomalies and neoplasia in animals and cells deficient in the large zinc finger protein KRC.
|
Genes Chromosomes Cancer
|
2002
|
0.87
|
|
44
|
Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.
|
Anal Chem
|
2013
|
0.87
|
|
45
|
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
|
Clin Cancer Res
|
2012
|
0.86
|
|
46
|
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
|
Leuk Res
|
2010
|
0.86
|
|
47
|
Differential role for cyclic AMP response element binding protein-1 in multiple stages of B cell development, differentiation, and survival.
|
J Immunol
|
2006
|
0.84
|
|
48
|
Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
|
Biomaterials
|
2013
|
0.83
|
|
49
|
A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application.
|
AAPS J
|
2010
|
0.83
|
|
50
|
Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.
|
MAbs
|
2010
|
0.83
|
|
51
|
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
|
MAbs
|
2013
|
0.82
|
|
52
|
The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma.
|
PLoS One
|
2009
|
0.82
|
|
53
|
Disruption of ZAS3 in mice alters NF-kappaB and AP-1 DNA binding and T-cell development.
|
Gene Expr
|
2007
|
0.82
|
|
54
|
IFN-gamma-mediated inhibition of antigen receptor-induced B cell proliferation and CREB-1 binding activity requires STAT-1 transcription factor.
|
Eur J Immunol
|
2003
|
0.81
|
|
55
|
OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway.
|
Br J Haematol
|
2011
|
0.78
|
|
56
|
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
|
J Pharm Sci
|
2008
|
0.77
|
|
57
|
Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.
|
J Biol Chem
|
2013
|
0.77
|
|
58
|
Role for Ets-2(Thr-72) transcription factor in stage-specific thymocyte development and survival.
|
J Biol Chem
|
2011
|
0.76
|
|
59
|
CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
|
Mol Pharm
|
2015
|
0.75
|
|
60
|
Antibody-based therapeutics for the treatment of human B cell malignancies.
|
Curr Allergy Asthma Rep
|
2013
|
0.75
|
|
61
|
Meeting report: The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010.
|
J Immunother
|
2010
|
0.75
|
|
62
|
Role of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis of bone marrow derived stem cells.
|
Indian J Exp Biol
|
2002
|
0.75
|